| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/17425255.2.1.3 |
| P698 | PubMed publication ID | 16863464 |
| P2093 | author name string | Barry P King | |
| Ann K Daly | |||
| P2860 | cites work | The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin | Q43917059 |
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol | Q43993665 | ||
| Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid | Q44237349 | ||
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. | Q44259188 | ||
| CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians | Q44365394 | ||
| Warfarin dose adjustments based on CYP2C9 genetic polymorphisms | Q44546032 | ||
| Differential expression and function of CYP2C isoforms in human intestine and liver | Q44584266 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients. | Q44684243 | ||
| Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions | Q44735365 | ||
| CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy | Q44787221 | ||
| Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | Q44787224 | ||
| 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients | Q44834814 | ||
| CYP2C9 genetic polymorphisms and warfarin | Q44849911 | ||
| Pharmacogenetics of acenocoumarol pharmacodynamics. | Q44872791 | ||
| Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers | Q44884449 | ||
| The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon | Q44884452 | ||
| Identification of a novel variant CYP2C9 allele in Chinese | Q44958934 | ||
| Discovery of new potentially defective alleles of human CYP2C9. | Q45000637 | ||
| Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype | Q45000639 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose | Q45062168 | ||
| Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status | Q45146000 | ||
| Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism | Q45193945 | ||
| Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose | Q46433362 | ||
| CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes | Q46496000 | ||
| Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status | Q46498399 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose | Q46560563 | ||
| Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. | Q52550127 | ||
| Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers | Q59153222 | ||
| Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase | Q22254865 | ||
| cDNA and amino acid sequences of two members of the human P450IIC gene subfamily | Q24631075 | ||
| Cytochrome P4502C9: an enzyme of major importance in human drug metabolism | Q24683497 | ||
| Crystal structure of human cytochrome P450 2C9 with bound warfarin | Q27641685 | ||
| CYP2C9 allelic variants: ethnic distribution and functional significance | Q28212029 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18 | Q28260682 | ||
| Isolation of the human cytochrome P-450 IIC8 gene: multiple glucocorticoid responsive elements in the 5' region | Q28271305 | ||
| A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data | Q31004538 | ||
| Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. | Q32072529 | ||
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution | Q33978913 | ||
| Risks factors for highly unstable response to oral anticoagulation: a case-control study | Q33986110 | ||
| Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. | Q34283903 | ||
| Pharmacogenetics of warfarin elimination and its clinical implications | Q34347249 | ||
| CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | Q34394876 | ||
| High clearance of (S)-warfarin in a warfarin-resistant subject | Q34403760 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Pharmacokinetic interactions with rifampicin : clinical relevance | Q35185727 | ||
| Clinical consequences of cytochrome P450 2C9 polymorphisms | Q36002222 | ||
| Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form | Q36420938 | ||
| Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions | Q38294095 | ||
| The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy | Q39703681 | ||
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. | Q40442584 | ||
| Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro | Q40520967 | ||
| Human P450 metabolism of warfarin | Q41334623 | ||
| Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis | Q43503989 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies | Q43705897 | ||
| Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients | Q43757356 | ||
| Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor | Q43779017 | ||
| Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers | Q43787614 | ||
| Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin | Q43820514 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin K | Q182338 |
| (E)-phytonadione | Q186093 | ||
| P304 | page(s) | 3-15 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Contribution of CYP2C9 to variability in vitamin K antagonist metabolism | |
| P478 | volume | 2 |
| Q37691210 | Cytochrome P450 2C9-CYP2C9. |
| Q46482316 | Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes |
| Q58388072 | Genetic association studies: where are we now? |
| Q44038170 | Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population |
| Q51739644 | Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. |
| Q47776901 | Pharmacogenetics: a general review on progress to date |
| Q37434634 | Pharmacogenomics of anticoagulants: steps toward personal dosage |
| Q24289220 | Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society |
Search more.